Data from the KEYNOTE-158 study, presented at the Society of Gynecological Oncology 2021 Virtual Annual Meeting on Women’s Cancer, showed durable responses in heavily pretreated patients with vulvar squamous cell carcinoma regardless of their PD-L1 status.
The combination of apatinib and pegylated liposomal doxorubicin improved the progression-free survival for patients with platinum-resistant or refractory ovarian cancer in comparison to doxorubicin alone, according to data from the phase 2 APPROVE trial.
Patients with advanced or recurrent endometrioid endometrial cancer had promising clinical outcomes following treatment with the combination of enzalutamide and carboplatin plus paclitaxel in the phase 2 ENPAC clinical trial.
Niraparib administered as maintenance therapy showed clinical benefit lasting beyond first progression in patients with platinum-sensitive recurrent ovarian cancer with or without germline BRCA mutations, according to the final results of the ENGOT-OV16/NOVA study.
Olaparib maintenance continues to show clinical activity in platinum-sensitive ovarian cancer, including in patients with somatic BRCA mutations and non-BRCA homologous recombination repair mutations.
In a phase 2 trial treatment with eribulin led to disease control and a favorable safety profile among patients with recurrent or advanced cervical cancer.
CA-125 surveillance alone could be used to detect disease progression in patients with advanced ovarian cancer and an abnormal CA-125 level at the beginning of frontline maintenance therapy with olaparib (Lynparza) and bevacizumab (Avastin), according to an analysis from the phase 3 PAOLA-1 that was presented at the SGO 2021 Annual Meeting on Women’s Cancer.
Compared with standard-of-care chemotherapy, treatment with the PARP inhibitor rucaparib led to a significant prolongation of progression-free survival and improved duration of response in patients with BRCA-mutated advanced, relapsed ovarian cancer, according to primary results from the phase 3 ARIEL4 trial.
Data from a post hoc analysis of the PRIMA/ENGOT-OV26/GOG-3012 phase III trial showed the efficacy of niraparib maintenance therapy for patients with ovarian cancer who had interval debulking surgery or visible residual disease.
Composite progression-free survival was not prolonged in patients with metastatic castration-resistant prostate cancer when the AKT kinase inhibitor capivasertib was added to chemotherapy. Despite this result, the combination demonstrated favorable overall survival.
Rajneesh Nath, MD, discusses his hypothesis on the benefits of targeted delivery of Iomab-B to the marrow in the older relapsed or refractory acute myeloid leukemia population.
For the treatment of patients with newly diagnosed acute graft-versus-host disease, itolizumab has demonstrated promise in part A of the multicenter dose-ascending phase 1b/2 EQUATE study.
Findings from the phase 3 CLEAR trial showed that the addition of lenvatinib to either pembrolizumab or everolimus led to an improvement in survival and response rates in comparison with sunitinib monotherapy in the first-line setting for patients with advanced renal cell carcinoma.
The addition of the oral hypoxia-inducible factor 2α inhibitor belzutifan to cabozantinib led to disease control in a majority of patients with previously treated advanced clear cell renal cell carcinoma, according to preliminary results from a phase 2 trial presented at the 2021 Genitourinary Cancers Symposium.
Cabozantinib reduced the risk of disease progression or death by 40% in comparison with sunitinib in patients with metastatic papillary renal cell carcinoma, according to findings from the randomized phase 2 SWOG 1500 study.
An increase in metastatic prostate cancer cases were reported in the United States and investigators are suggesting that this may be due, in part, to reductions in prostate-specific antigen, according to epidemiologic data from a study presented during the 2021 Genitourinary Cancers Symposium.
In patient with metastatic renal cell carcinoma who have brain metastases, treatment with cabozantinib displayed significant intracranial and extracranial, results from a retrospective analysis presented during the 2021 Genitourinary Cancers Symposium show.
A molecular signature has been identified that can characterize long-term responders from treatment with apalutamide and androgen deprivation therapy in patients with nonmetastatic castration-resistant prostate cancer, according to findings, presented at the 2021 Genitourinary Cancers Symposium.
In patients with non-muscle invasive bladder cancer carcinoma in-situ who were unresponsive to Bacillus Calmette-Guerin, the addition of N-803 induced a high rate of complete responses, findings from a cohort of the phase 2/3 QUILT-3.032 study showed.
Localized metastatic lesions were detected with a high correct localization rate (CLR) and positive predictive value (PPV) with the investigational prostate-specific membrane antigen (PSMA)–targeted PET imaging agent 18F-DCFPyL.
Patrick G. Pilié, MD, explains how the safety profile of darolutamide, as seen in the ARAMIS clinical trial, differs from those of enzalutamide and apalutamide.
Apalutamide in combination with androgen deprivation therapy led to a reduction in the risk of death of 35% in comparison with ADT alone for patients with metastatic castration-sensitive prostate cancer in a final analysis of the phase 3 TITAN trial.
Results from the phase 3 CheckMate-274 trial showed that nivolumab following surgery improved disease-free survival compared with placebo for patients with muscle-invasive urothelial carcinoma, according a presentation given during the 2021 ASCO Genitourinary Cancer Symposium.
Enfortumab vedotin demonstrated superior efficacy compared with chemotherapy in patients with advanced urothelial carcinoma who had previously received platinum-based chemotherapy and PD-1/L1 inhibition, according to results from a primary analysis of the phase 3 EV-301 clinical trial.
Response rates to enfortumab vedotin in cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer who received prior PD-1/PD-L1 inhibitors were the highest numerically observed for any regimen, according to findings from study EV-201 presented at the 2021 American Society of Clinical Oncology Genitourinary Cancer Symposium.
Eleni Efstathiou, MD, PhD, provides background on the ARAMIS trial of darolutamide compared with placebo as treatment of patients with nonmetastatic castration-resistant prostate cancer.
Nivolumab in combination with cabozantinib continues to demonstrate superior efficacy over sunitinib monotherapy in the frontline treatment of patients with advanced renal cell carcinoma, according to extended follow-up data from the phase 3 CheckMate 9ER trial.
A novel prostate-specific membrane antigen–targeted radiopharmaceutical for positron emission tomography known as 18F-DCFPyL, may help to identify occult prostate cancer and more accurately characterize disease burden, according to a subanalysis of the OSPREY trial presented during the 2021 Genitourinary Cancers Symposium.
In patients with nonmetastatic castration-resistant prostate cancer (nmCRPC), crossover from placebo to darolutamide (Nubeqa) appeared have minimal impact on the overall survival (OS) benefit observed with the androgen receptor inhibitor in the pivotal phase 3 ARAMIS trial.
The VEGF tyrosine kinase inhibitor tivozanib hydrochloride demonstrated a significantly increased quality-adjusted time without symptoms of disease and toxicity as third- or fourth-line therapy in patients with metastatic renal cell carcinoma compared with sorafenib in the phase 3 TIVO-3 trial.